{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361137043463268992.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1038/nm935"}},{"identifier":{"@type":"URI","@value":"http://www.nature.com/articles/nm935.pdf"}},{"identifier":{"@type":"URI","@value":"http://www.nature.com/articles/nm935"}}],"dc:title":[{"@value":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381137043463268992","@type":"Researcher","foaf:name":[{"@value":"Vincent H Gattone"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137043463268993","@type":"Researcher","foaf:name":[{"@value":"Xiaofang Wang"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137043463268994","@type":"Researcher","foaf:name":[{"@value":"Peter C Harris"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137043463268995","@type":"Researcher","foaf:name":[{"@value":"Vicente E Torres"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"10788956"},{"@type":"EISSN","@value":"1546170X"}],"prism:publicationName":[{"@value":"Nature Medicine"}],"dc:publisher":[{"@value":"Springer Science and Business Media LLC"}],"prism:publicationDate":"2003-09-21","prism:volume":"9","prism:number":"10","prism:startingPage":"1323","prism:endingPage":"1326"},"reviewed":"false","dc:rights":["http://www.springer.com/tdm"],"url":[{"@id":"http://www.nature.com/articles/nm935.pdf"},{"@id":"http://www.nature.com/articles/nm935"}],"createdAt":"2003-09-22","modifiedAt":"2023-05-18","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050001339067079552","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Monkeys mutant for PKD1 recapitulate human autosomal dominant polycystic kidney disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1050282810927601664","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Caroli's Disease: Current Knowledge of Its Biliary Pathogenesis Obtained from an Orthologous Rat Model"}]},{"@id":"https://cir.nii.ac.jp/crid/1050297847286571520","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A bell‐shaped pattern of urinary aquaporin‐2‐bearing extracellular vesicle release in an experimental model of nephronophthisis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360002215824057984","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Proteomic analysis of AQP11-null kidney: Proximal tubular type polycystic kidney disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360005518347767040","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285706972141952","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Distinct oxylipin alterations in diverse models of cystic kidney diseases"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285712608694144","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Increased salt intake does not worsen the progression of renal cystic disease in high water-loaded PCK rats"}]},{"@id":"https://cir.nii.ac.jp/crid/1360294643837521664","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Urinary Aquaporin 2 as a Potential Indicator Predicting Tolvaptan Response in Patients With ADPKD"}]},{"@id":"https://cir.nii.ac.jp/crid/1360298757415203840","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Development of gene silencer pyrrole-imidazole polyamides targeting GSK3β for treatment of polycystic kidney diseases"}]},{"@id":"https://cir.nii.ac.jp/crid/1360572092493508608","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Regional Variance of the Early Use of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360580232150345344","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long-Term Outcomes of Longitudinal Efficacy Study With Tolvaptan in ADPKD"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846641760746112","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"A cleavage product of Polycystin-1 is a mitochondrial matrix protein that affects mitochondria morphology and function when heterologously expressed"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848661909539456","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Slp2-a controls renal epithelial cell size through regulation of Rap–ezrin signaling independently of Rab27"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848662539024384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861704785137920","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Comparative Efficacy of Pharmacological Treatments for Adults With Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001206445851136","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"多発性嚢胞腎の病態と治療：新たな展開"},{"@language":"en","@value":"The Pathology and New Treatment of ADPKD"},{"@value":"医学と医療の最前線 多発性囊胞腎の病態と治療 : 新たな展開"},{"@language":"ja-Kana","@value":"イガク ト イリョウ ノ サイゼンセン タハツセイノウホウジン ノ ビョウタイ ト チリョウ : アラタ ナ テンカイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390297272115204352","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Copeptin is associated with microalbuminuria and renal function in the general Japanese population"}]},{"@id":"https://cir.nii.ac.jp/crid/1390574058671320192","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Tolvaptan, a vasopressin V<sub>2</sub> receptor antagonist, is the world’s first approved drug for treatment of autosomal dominant polycystic kidney disease (ADPKD)"},{"@language":"ja","@value":"世界初の多発性嚢胞腎治療薬トルバプタン"}]},{"@id":"https://cir.nii.ac.jp/crid/1390845713066890368","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"1. Antihypertensive Drug and Vasopressin Receptor Antagonist Treatment for Polycystic Kidney Disease"},{"@language":"ja","@value":"1．多発性囊胞腎の降圧薬治療・バソプレシン受容体拮抗薬治療"},{"@value":"多発性囊胞腎の降圧薬治療・バソプレシン受容体拮抗薬治療"},{"@language":"ja-Kana","@value":"タハツセイノウホウジン ノ コウアツヤク チリョウ ・ バソプレシン ジュヨウタイ キッコウヤク チリョウ"}]},{"@id":"https://cir.nii.ac.jp/crid/1391975276373395968","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Clinical characteristics associated with 1-year tolvaptan efficacy in autosomal dominant polycystic kidney disease with a wide range of kidney functions"}]},{"@id":"https://cir.nii.ac.jp/crid/2050307417127901056","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease"}]},{"@id":"https://cir.nii.ac.jp/crid/2050588892097689472","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Exploring urinary biomarkers in autosomal dominant polycystic kidney disease"}]},{"@id":"https://cir.nii.ac.jp/crid/2051151842055064064","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Hydrochlorothiazide ameliorates polyuria caused by tolvaptan treatment of polycystic kidney disease in PCK rats"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1038/nm935"},{"@type":"CROSSREF","@value":"10.1007/s10157-014-1078-7_references_DOI_1sbohogRIvLsFlfVVpyWmycVLKJ"},{"@type":"CROSSREF","@value":"10.1155/2012/107945_references_DOI_1sbohogRIvLsFlfVVpyWmycVLKJ"},{"@type":"CROSSREF","@value":"10.14814/phy2.14092_references_DOI_1sbohogRIvLsFlfVVpyWmycVLKJ"},{"@type":"CROSSREF","@value":"10.1038/s41440-019-0284-9_references_DOI_1sbohogRIvLsFlfVVpyWmycVLKJ"},{"@type":"CROSSREF","@value":"10.1371/journal.pone.0207461_references_DOI_1sbohogRIvLsFlfVVpyWmycVLKJ"},{"@type":"CROSSREF","@value":"10.1038/s41467-019-13398-6_references_DOI_1sbohogRIvLsFlfVVpyWmycVLKJ"},{"@type":"CROSSREF","@value":"10.1007/s10157-020-02009-0_references_DOI_1sbohogRIvLsFlfVVpyWmycVLKJ"},{"@type":"CROSSREF","@value":"10.2169/naika.107.834_references_DOI_1sbohogRIvLsFlfVVpyWmycVLKJ"},{"@type":"CROSSREF","@value":"10.1016/j.ekir.2021.06.033_references_DOI_1sbohogRIvLsFlfVVpyWmycVLKJ"},{"@type":"CROSSREF","@value":"10.1016/j.jphs.2023.01.001_references_DOI_1sbohogRIvLsFlfVVpyWmycVLKJ"},{"@type":"CROSSREF","@value":"10.2152/jmi.67.315_references_DOI_1sbohogRIvLsFlfVVpyWmycVLKJ"},{"@type":"CROSSREF","@value":"10.34067/kid.0002262020_references_DOI_1sbohogRIvLsFlfVVpyWmycVLKJ"},{"@type":"CROSSREF","@value":"10.1254/fpj.22006_references_DOI_1sbohogRIvLsFlfVVpyWmycVLKJ"},{"@type":"CROSSREF","@value":"10.1507/endocrj.ej23-0005_references_DOI_1sbohogRIvLsFlfVVpyWmycVLKJ"},{"@type":"CROSSREF","@value":"10.1016/j.ekir.2021.11.034_references_DOI_1sbohogRIvLsFlfVVpyWmycVLKJ"},{"@type":"CROSSREF","@value":"10.1038/s41598-018-20856-6_references_DOI_1sbohogRIvLsFlfVVpyWmycVLKJ"},{"@type":"CROSSREF","@value":"10.1007/s10157-018-1669-9_references_DOI_1sbohogRIvLsFlfVVpyWmycVLKJ"},{"@type":"CROSSREF","@value":"10.1371/journal.pone.0177934_references_DOI_1sbohogRIvLsFlfVVpyWmycVLKJ"},{"@type":"CROSSREF","@value":"10.1242/jcs.134056_references_DOI_1sbohogRIvLsFlfVVpyWmycVLKJ"},{"@type":"CROSSREF","@value":"10.1016/j.bbalip.2017.08.005_references_DOI_1sbohogRIvLsFlfVVpyWmycVLKJ"},{"@type":"CROSSREF","@value":"10.3389/fphar.2022.885457_references_DOI_1sbohogRIvLsFlfVVpyWmycVLKJ"},{"@type":"CROSSREF","@value":"10.2169/naika.103.978_references_DOI_1sbohogRIvLsFlfVVpyWmycVLKJ"},{"@type":"CROSSREF","@value":"10.1016/j.bbrep.2017.11.003_references_DOI_1sbohogRIvLsFlfVVpyWmycVLKJ"}]}